6Taguchi T,Wakui A,Nabeya K,et al.A phaseⅡclinical study of cis-diammine glycolato platinum,254-S,for gastrointestinal cancers.254-S Gastrointestinal Cancer Study Group[J].Gan To Kagaku Ryoho,1992,19(4):483-488. 被引量：1
7Kanai M,Matsumoto S,Nishimura T,et al.Retrospective analysis of 27 consecutive patients treated with docetaxel/nedaplatin combination therapy as a second-line regimen for advanced esophageal cancer[J].Int J Clin Oncol,2007,12(3):224-227. 被引量：1
10Sumi H,Ohtsu A,Boku N,et al.A case of inoperable esophageal carcinoma with hepatic and nodal metastases which showed a long-term survival after chemoradiotherapy including nedaplatin [J].JpnJ Clin Oncol,2000,30(9):406～409 被引量：1
2Long J,Luo GP,Xiao ZW,et al.Cancer statistics:currentdiagnosis and treatment of pancreatic cancer in Shanghai,China[J].Cancer Lett,2014,346(2):273-277. 被引量：1
3Clark CE,Beatty GL,Vonderheide RH.Immunosurveillanceof pancreatic adenocarcinoma:insights from geneticallyengineered mouse models of cancer [J].Cancer Lett ,2009 ,279(1):1-7. 被引量：1
4Clark CE,Hingorani SR,Mick R,et al.Dynamics of theimmune reaction to pancreatic cancer from inception toinvasion[J].Cancer Res,2007,67(19):9518-9527. 被引量：1
5Mellman I,Coukos G,Dranoff G.Cancer immunotherapycomes of age[J].Nature,2011,480(7378):480-489. 被引量：1
6Xu YF,Lu Y,Cheng H,et al.Abnormal distribution ofperipheral lymphocyte subsets induced by PDACmodulates overall survival[J].Pancreatology ,2014,14 (4):295-301. 被引量：1
